Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Sponsor: Celgene
Summary
The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapsed and/or refractory multiple myeloma.
Official title: A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
156
Start Date
2024-02-27
Completion Date
2025-05-30
Last Updated
2025-04-04
Healthy Volunteers
No
Conditions
Interventions
Alnuctamab
Specified dose on specified days
Mezigdomide
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Locations (6)
Local Institution - 0033
Birmingham, Alabama, United States
Local Institution - 0035
New Haven, Connecticut, United States
Local Institution - 0018
New York, New York, United States
Local Institution - 0021
Petah Tikva, Central District, Israel
Local Institution - 0030
Ramat Gan, Central District, Israel
Local Institution - 0020
Jerusalem, Israel